Systemic and mucosal differences in hiv burden, immune, and therapeutic responses

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 5, 2011, Pages 401-411

  Wahl, Sharon M ^a   Redford, Maryann ^a   Christensen, Shawna ^b   MacK, Wendy ^b   Cohn, Jon ^c   Janoff, Edward N ^d   Mestecky, Jiri ^e   Jenson, Hal B ^f   Navazesh, Mahvash ^g   Cohen, Mardge ^h   Reichelderfer, Patricia ⁱ   Kovacs, Andrea ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e University of Alabama at Birmingham   (United States)

^f University of Texas Health Science Center   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h Jr Hospital of Cook County   (United States)

ⁱ EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

adaptive immunity; HIV 1; IgA; innate immunity; mucosa; SLPI

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PROTEINASE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; THROMBOSPONDIN; VIRUS RNA;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; FEMALE; GENITAL SYSTEM; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MOUTH CAVITY; MUCOSA; PRIORITY JOURNAL; SALIVA; VIRULENCE; VIRUS LOAD; VIRUS SHEDDING;

ADAPTIVE IMMUNITY; ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; GENITALIA, FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; MIDDLE AGED; MOUTH MUCOSA; MUCOUS MEMBRANE; RNA, VIRAL; SALIVA; TREATMENT OUTCOME; VIRAL LOAD; VIRUS SHEDDING; YOUNG ADULT;

EID: 79953037632     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31820cdfdb     Document Type: Article

References (54)

1. Smith P, Wahl S. Immunobiology of mucosal HIV-1 infection. In: Mestecky J, Bienenstoch J, Lamm ME, et al, eds. Mucosal Immunology. 3rd ed. Amsterdam, The Netherlands: Elsevier/Academic Press; 1199-1203.
2. Anderson DJ, Politch JA, Tucker LD, et al. Quantitation of mediators of inflammation and immunity in genital tract secretions and their relevance to HIV type 1 transmission. AIDS Res Hum Retroviruses. 1998; 14(Suppl 1):S43-S49. (Pubitemid 28208888)
3. Kovacs A, Wasserman SS, Burns D, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet. 2001;358:1593-1601. (Pubitemid 33101909)
4. Shugars DC, Wahl SM. The role of the oral environment in HIV-1 transmission. J Am Dent Assoc. 1998;129:851-858. (Pubitemid 128459421)
5. Schacker T, Collier AC, Hughes J, et al. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996;125: 257-264. (Pubitemid 126449269)
6. Page-Shafer K, Shiboski CH, Osmond DH, et al. Risk of HIV infection attributable to oral sex among men who have sex with men and in the population of men who have sex with men. AIDS. 2002;16: 2350-2352. (Pubitemid 35449028)
7. Bruce AJ, Rogers RS III. Oral manifestations of sexually transmitted diseases. Clin Dermatol. 2004;22:520-527. (Pubitemid 40017674)
8. Gaur A, Dominguez K, Kalish M, et al. Practice of offering a child pre-masticated food: an unrecognized possible risk factor for HIV Triansmission. Paper presented at: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA.
9. Hussain LA, Lehner T. Comparative investigation of Langerhans' cells and potential receptors for HIV in oral, genitourinary and rectal epithelia. Immunology. 1995;85:475-484.
10. McNeely TB, Shugars DC, Rosendahl M, et al. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood. 1997;90: 1141-1149. (Pubitemid 27314150)
11. McNeely TB, Dealy M, Dripps DJ, et al. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest. 1995;96:456-464.
12. Crombie R, Silverstein RL, MacLow C, et al. Identification of a CD36-related thrombospondin 1-binding domain in HIV-1 envelope glycopro-tein gp120: relationship to HIV-1-specific inhibitory factors in human saliva. J Exp Med. 1998;187:25-35. (Pubitemid 28044817)
13. Malamud D, Wahl SM. The mouth: a gateway or a trap for HIV? AIDS. 2010;24:5-16.
14. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998;9:117-125.
15. Pellett PE, Spira TJ, Bagasra O, et al. Multicenter comparison of PCR assays for detection of human herpesvirus 8 DNA in semen. J Clin Microbiol. 1999;37:1298-1301. (Pubitemid 29187787)
16. Jenson HB, Ench Y, Sumaya C, et al.Manual of Clinical Laboratory Immunology. 5th ed. Washington, DC: American Society for Microbiology; 1997.
17. Schacker T, Ryncarz AJ, Goddard J, et al. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA. 1998;280:61-66. (Pubitemid 28414998)
18. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst. 1999;91: 226-236. (Pubitemid 29090991)
19. Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983; 74:14-22. (Pubitemid 13221599)
20. Division of AIDS N. DAIDS Virology Manual for HIV Laboratories. Washington, DC: US Department of Health and Human Services; 1997.
21. Nowicki MJ, Benning L, Bremer JW, et al. Longitudinal variability of human immunodeficiency virus type 1 RNA viral load measurements by nucleic acid sequence-based amplification and NucliSens assays in a large multicenter study. J Clin Microbiol. 2001;39:3760-3763. (Pubitemid 32954541)
22. Mestecky J, Jackson S, Moldoveanu Z, et al. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res Hum Retroviruses. 2004;20:972-988. (Pubitemid 39369704)
23. Mestecky J, Moldoveanu Z, Russell MW. Immunologic uniqueness of the genital tract: challenge for vaccine development. Am J Reprod Immunol. 2005;53:208-214. (Pubitemid 40542802)
24. Powers KA, Poole C, Pettifor AE, et al. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8:553-563.
25. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191:1403-1409. (Pubitemid 40563350)
26. Orenstein JM, Wahl SM. The macrophage origin of the HIV-expressing multinucleated giant cells in hyperplastic tonsils and adenoids. Ultrastruct Pathol. 1999;23:79-91. (Pubitemid 29207179)
27. Hiemstra PS, Fernie-King BA, McMichael J, et al. Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapeutics. Curr Pharm Des. 2004;10: 2891-2905. (Pubitemid 39172069)
28. Ma G, Greenwell-Wild T, Lei K, et al. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med. 2004;200:1337-1346. (Pubitemid 39552574)
29. Wahl SM, Greenwell-Wild T, Vazquez N. HIV accomplices and adversaries in macrophage infection. J Leukoc Biol. 2006;80:973-983. (Pubitemid 44646303)
30. Vogelmeier C, Hubbard RC, Fells GA, et al. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J Clin Invest. 1991;87: 482-488.
31. Draper D, Donohoe W, Mortimer L, et al. Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor. J Infect Dis. 1998;178:815-819. (Pubitemid 28397230)
32. Jana NK, Gray LR, Shugars DC. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity. J Virol. 2005;79:6432-6440. (Pubitemid 40617246)
33. Chattopadhyay A, Gray LR, Patton LL, et al. Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons. Infect Immun. 2004;72:1956-1963. (Pubitemid 38419906)
34. Fakioglu E, Wilson SS, Mesquita PM, et al. Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J Virol. 2008;82:9337-9344.
35. Smith D. HIV and herpes co-infection, an unfortunate partnership. J HIV Ther. 2004;9:1-3.
36. Celum C, Levine R, Weaver M, et al. Genital herpes and human immunodeficiency virus: double trouble. Bull World Health Organ. 2004; 82:447-453. (Pubitemid 38828431)
37. Pillay K, Coutsoudis A, Agadzi-Naqvi AK, et al. Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. J Infect Dis. 2001;183: 653-656. (Pubitemid 32147523)
38. Farquhar C, VanCott TC, Mbori-Ngacha DA, et al. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J Infect Dis. 2002;186:1173-1176. (Pubitemid 35177123)
39. Karray S, Juompan L, Maroun RC, et al. Structural basis of the gp120 superantigen-binding site on human immunoglobulins. J Immunol. 1998; 161:6681-6688. (Pubitemid 28562210)
40. Xu W, He B, Chiu A, et al. Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol. 2007;8:294-303. (Pubitemid 46745379)
41. Morris L, Binley JM, Clas BA, et al. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med. 1998;188:233-245. (Pubitemid 28357752)
42. Moir S, Fauci AS. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol. 2008;122:12-19; quiz 20-11.
43. Hirbod T, Kaul R, Reichard C, et al. HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS. 2008;22:727-735. (Pubitemid 351450641)
44. Kaul R, Plummer F, Clerici M, et al. Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. AIDS. 2001;15:431-432. (Pubitemid 32163839)
45. Moja P, Tranchat C, Tchou I, et al. Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected patients. J Infect Dis. 2000;181:1607-1613. (Pubitemid 30387751)
46. Devito C, Hinkula J, Kaul R, et al. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J Acquir Immune Defic Syndr. 2002; 30:413-420. (Pubitemid 34857316)
47. Janoff EN, Wahl SM, Thomas K, et al. Modulation of human immunodeficiency virus type 1 infection of human monocytes by IgA. J Infect Dis. 1995;172:855-858.
48. Chomont N, Hocini H, Gody JC, et al. Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells. Virology. 2008;370:246-254. (Pubitemid 350199680)
49. Watkins DI, Burton DR, Kallas EG, et al. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med. 2008;14: 617-621. (Pubitemid 351809543)
50. Kuhn L, Trabattoni D, Kankasa C, et al. Hiv-specific secretory IgA in breast milk of HIV-positive mothers is not associated with protection against HIV transmission among breast-fed infants. J Pediatr. 2006;149: 611-616. (Pubitemid 44767685)
51. Wright A, Lamm ME, Huang YT. Excretion of HIV-1 through polarized epithelium by immunoglobulin A. J Virol. 2008;82:11526-11535.
52. Gage JR, Sandhu AK, Nihira M, et al. Effects of human papillomavirus-associated cells on human immunodeficiency virus gene expression. Obstet Gynecol. 2000;96:879-885.
53. Yurochko AD, Huong SM, Huang ES. Identification of human cytomegalovirus target sequences in the human immunodeficiency virus long terminal repeat. Potential role of IE2-86 binding to sequences between -120 and -20 in promoter transactivation. J Hum Virol. 1999;2: 81-90. (Pubitemid 30257657)
54. Pitt J, Schluchter M, Jenson H, et al. Maternal and perinatal factors related to maternal-infant transmission of HIV-1 in the P2C2 HIV study: the role of EBV shedding. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV-1 Infection (P2C2 HIV) Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:462-470.